Based on recent data demonstrating the efficacy of pembrolizumab in R/M SCCHN among patients with a combined positive score (CPS) ≥1 for PD‐L1 expression,7 pembrolizumab alone or in combination with platinum‐5‐FU has become a first‐line treatment option for this patient subpopulation. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.